For many diabetics, an available supply of insulin is the difference between life and death. But in the US, the price of insulin is increasing, costing on average about six-thousand dollars a year.
To ensure the ongoing affordability of generic medications for Americans, BCBS is committing $55 million to establish a partnership with Civica Rx to reduce costs of generics for consumers.
The mechanisms of pharmaceutical rebates in Medicare Part D and commercial insurance.
Recent pharmaceutical innovations offer unprecedented possibilities for curing, treating, or preventing a range of diseases. However, patients, providers and payers alike have raised concerns about the affordability and sustainability of these drugs.